BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment
Abstract Hepatocellular carcinoma (HCC) represents a global health challenge with limited therapeutic options. Anti-angiogenic immune checkpoint inhibitor-based combination therapy has been introduced for progressed HCC, but improves survival only in a subset of HCC patients. Tyrosine-kinase inhibit...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group
2021-07-01
|
| Seri Bilgileri: | Cell Death and Disease |
| Online Erişim: | https://doi.org/10.1038/s41419-021-04020-z |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|